Phase II trial of HER2-PET/CT using 68Ga-anti-HER2 VHH1 for characterization of HER2 presence in brain metastases of breast cancer patients

Authors:

Abstract
Background: Brain metastases form a challenge in breast cancer patients, especially in HER2+ patients whose peripheral metastases can often be controlled using standard-of-care HER2 regimens, but with relapse or progression in the brain. This determines survival for such patients. Penetration in brain lesions as well as the therapeutic outcome can be hampered due to the particular tumour microenvironment. The here used anti-HER2 agent is a single-domain antibody or nanobody that targets HER2 with nanomolar affinity but with a size that is ten-fold smaller than conventional antibodies. This could be an important factor in diagnostic and even therapeutic efficacy for nanobody radiopharmaceuticals. The 68Ga-anti-HER2 VHH1 has been successfully tested in phase I trial in 20 breast cancer patients, confirming safety and tolerability, low irradiation burden for PET/CT procedures and high uptake in HER2-positive lesions. The aim of the current study is to test its application potential for PET/CT imaging of breast cancer brain metastases. If favourable, this would support the development therapeutic analogues for targeted radionuclide therapy.